OBJECTIVE We aimed to compare serum and urinary HER2/neu levels between healthy control group and patients with non-muscle invasive bladder cancer. Additionally, we evaluated relationship of HER2/neu levels with tumor stage, grade, recurrence and progression. MATERIALS AND METHODS Fourty-four patients with primary non-muscle invasive bladder tumors (Group 2) and 40 healthy control group (Grou...

ownload tment of human epidermal growth factor receptor 2 (HER2/neu)-expressing breast cancer patients with oclonal antibody (mAb) directed against HER2/neu improves the outcome of chemotherapy. In cases in remission is observed, antibody-dependent cell-mediated cytotoxicity (ADCC) seems to be one of the echanisms of anti-HER2/neu mAb action, implicating Fcγ receptors (FcγRs) in this tumoricida...

The neu (c-erbB-2, Her-2) protooncogene is amplified and overexpressed in 20-30% of human breast cancers. Although transgenic mouse models have illustrated the role of Neu in the induction of mammary tumors, Neu expression in these models is driven by a strong viral promoter of questionable relevance to the human disease. To ascertain whether expression of activated Neu under the control of the...

OBJECTIVES The HER-2/neu oncogene is overexpressed in many types of cancer and especially in 25% to 30% of breast cancers. Single reports mention HER-2/neu positivity in hematological malignancies like Hodgkins's disease and even diffuse large-cell lymphoma. OBJECTIVE To test for HER-2/neu overexpression in patients with non-Hodgkin's lymphoma and the possible role of the recombinant monoclon...

A major barrier to successful antitumor vaccination is tolerance of high-avidity T cells specific to tumor antigens. In keeping with this notion, HER-2/neu (neu)-targeted vaccines, which raise strong CD8(+) T cell responses to a dominant peptide (RNEU(420-429)) in WT FVB/N mice and protect them from a neu-expressing tumor challenge, fail to do so in MMTV-neu (neu-N) transgenic mice. However, tr...

BACKGROUND Amplification and/or overexpression of HER-2/neu are associated with poor clinical outcome in several epithelial tumors. However, the exact prognostic role of HER-2/neu expression in testicular germ-cell tumors is equivocal. PATIENTS AND METHODS Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu alterations of 59 primary testicular teratomas and mixed ...

The epidermal growth factor receptor HER2/neu is expressed on various cancers and represents a negative prognostic marker, but is also a target for the therapeutic monoclonal antibody Trastuzumab. In about 30% of cases, HER2/neu is expressed on acute lymphoblastic leukemia (ALL) cells and was proposed to be associated with a deleterious prognosis. Here we evaluated clinical data from 65 ALL pat...

Nötrofil/lenfosit oranı (NEU/LYM), monosit/lenfosit (MONO/LYM), ve platelet/lenfosit (PLT/LYM) inflamasyonunun ucuz, tekrar kullanılabilen biyobelirteçlerini oluşturmaktadır. Bu çalışma ilk defa parvovirus enfeksiyonu (PVE) şekillenmiş köpeklerde NEU/LYM, MONO/LYM PLT/LYM değerlerini ortaya koymaktadır. Çalışmanın amacını ise tedavi öncesi PVE ile pozitif köpeklerin değerlerinin, sağlıklı kontr...

We examined the therapeutic efficacy of xenogenic human N'-terminal neu DNA vaccine and autologous mouse N'-terminal neu DNA vaccine on MBT-2 tumor cells in C3H mice. Intramuscular injection of xenogenic and autologous neu DNA vaccines produced comparable therapeutic efficacies. Mouse and human N'-neu DNA vaccine induced tumor infiltration of CD8(+) T cells, while the human vaccine was less eff...